Search results
Showing 121 to 135 of 157 results for fibrosis
Urinary tract infection (recurrent): antimicrobial prescribing (NG112)
This guideline sets out an antimicrobial prescribing strategy for preventing recurrent urinary tract infections in children, young people and adults who do not have a catheter. It aims to optimise antibiotic use and reduce antibiotic resistance.
Highly specialised technologies evaluation committee members
Highly specialised technologies evaluation committee members
Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.
UHS specialities include large regional intestinal failure, cystic fibrosis, oncology, cardiac and neurology units with a high number...
NICE has developed a medtech innovation briefing (MIB) on OxyMask for delivering oxygen therapy .
with idiopathic pulmonary fibrosis:- Does pulmonary rehabilitation improve outcomes for people with idiopathic pulmonary...
This guideline sets out an antimicrobial prescribing strategy for acute otitis media (ear infection). It aims to limit antibiotic use and reduce antimicrobial resistance. Acute otitis media can be caused by viruses or bacteria. It lasts for about a week, and most children get better in 3 days without antibiotics. Serious complications are rare.
Artificial intelligence for analysing chest CT images (MIB243)
NICE has developed a medtech innovation briefing (MIB) on artificial intelligence for analysing chest CT images .
This evidence summary has been updated and replaced by NICE guideline NG78.
Non-cystic fibrosis bronchiectasis: colistimethate sodium (ESUOM25)
This evidence summary has been updated and replaced by NICE guideline NG117.
Non-cystic fibrosis bronchiectasis: inhaled tobramycin (ES12)
This evidence summary has been updated and replaced by NICE guideline NG117.
Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)
Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making
Non-cystic fibrosis bronchiectasis: long-term azithromycin (ESUOM38)
This evidence summary has been updated and replaced by NICE guideline NG117.
C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)
Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making
NICE has developed a medtech innovation briefing (MIB) on The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs .